GlassScriptPhysician profile
Robert Fong Sing
NPI 1598853301
$9,979.06
in general payments reported to CMS, 2019-2025
54 companies · $2,352 in 2025
The $2,352 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,383 · 2020: $634 · 2021: $1,196 · 2022: $1,470 · 2023: $1,463 · 2024: $1,481 · 2025: $2,352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,295.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,293.33 | 2019-2025 | Farxiga, Airsupra, Fasenra |
| Abbvie INC. | $846.18 | 2021-2025 | Vraylar |
| Novo Nordisk INC | $844.94 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $626.76 | 2019-2025 | Zepbound, Mounjaro, Emgality |
| Axsome Therapeutics, INC. | $530.20 | 2022-2025 | Auvelity |
| Collegium Pharmaceutical, INC. | $437.20 | 2019-2025 | Belbuca |
| Pfizer INC. | $427.42 | 2019-2025 | |
| Amarin Pharma, INC. | $406.92 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $339.22 | 2019-2025 | Seglentis, Zoryve, Livalo |
| Idorsia Pharmaceuticals US INC | $335.67 | 2022-2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $302.94 | 2019-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $290.15 | 2023-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $242.92 | 2021-2025 | Rexulti, Abilify Mycite |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $234.63 | 2019-2021 | |
| Impel Pharmaceuticals INC. | $202.50 | 2023 | Trudhesa |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Sing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.